Stephen K. Brannan - 01 Nov 2021 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Nov 2021
Net transactions value
-$1,000,256
Form type
4
Filing time
03 Nov 2021, 16:17:11 UTC
Next filing
02 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $13,625 +2,500 +17% $5.45* 17,500 01 Nov 2021 Direct
transaction KRTX Common Stock Options Exercise $749 +103 +0.59% $7.27* 17,603 01 Nov 2021 Direct
transaction KRTX Common Stock Sale $14,077 -103 -0.59% $136.67 17,500 01 Nov 2021 Direct F1
transaction KRTX Common Stock Options Exercise $41,556 +7,625 +44% $5.45* 25,125 01 Nov 2021 Direct
transaction KRTX Common Stock Sale $1,042,109 -7,625 -30% $136.67 17,500 01 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -2,500 -4.2% $0.000000 56,329 01 Nov 2021 Common Stock 2,500 $5.45 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -103 -0.21% $0.000000 48,030 01 Nov 2021 Common Stock 103 $7.27 Direct F3
transaction KRTX Option (right to buy) Options Exercise $0 -7,625 -14% $0.000000 48,704 01 Nov 2021 Common Stock 7,625 $5.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2 This option vests as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3 This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.